FLUOROURACILUM

Neuroendocrine Tumors

ITM Solucin GmbHSmall moleculePhase 3Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 54/ 100
Competitive Position: 73/ 100

Competitive context

55 Active assets in the Neuroendocrine Tumors cohort.

Asset / Sponsor	Phase	Rating
Irinotecan First Affiliated Hospital Xi'an Jiaotong University	Phase 4	BB
Surufatinib Shanghai Changzheng Hospital	Phase 3	BB
Oxodotreotide Fundación de investigación HM	Phase 3	BB
Eloxatin ITM Solucin GmbH	Phase 3	BB
Everolimus Exelixis	Phase 3	BB

View all 50 →

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant

A

Indicative ·

82 / 100

Unresectable or Metastatic Colorectal CancerDormant

BBB

Indicative ·

79 / 100

exocrine pancreatic carcinomaDormant

BBB

Indicative ·

78 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.